Blood Markers of Blood Vessel Lining Damage in Adults With New Hypertension
Compares small blood particles in adults with and without newly diagnosed, untreated hypertension.
Plain-language title generated from the registry record
Registry title: Endothelial Extracellular Vesicles as Biomarkers of Endothelial Activation in Adults With Newly Diagnosed Hypertension
Key facts
- Where
- Osijek, CroatiaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed hypertension who have never been treated for it, and adults with normal blood pressure for comparison.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed primary hypertension (untreated), or normal blood pressure, classified by European Society of Hypertension (ESH) guidelines.
- Earlier treatment
- People with hypertension must not have taken blood pressure medicine before.
Main reasons for not taking part
- Secondary hypertension
- History of cardiovascular disease (other than the new primary hypertension)
- Diabetes, chronic kidney disease, cerebrovascular disease or peripheral arterial disease
- Active cancer, or acute or chronic inflammatory or infectious disease
- Pregnancy or breastfeeding
Read by machine on 9 November 2026.
Where in Croatia
- Faculty of Medicine OsijekOsijek, CroatiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Josip Juraj Strossmayer University of Osijek
- Trial code
- NCT07728630
- Record updated
- 27 July 2026
- Original description
Hypertension is associated with endothelial dysfunction, an early event in the development of cardiovascular disease. Endothelial extracellular vesicles (EEVs) have emerged as promising biomarkers of endothelial activation and vascular injury; however, their relationship with blood pressure and microvascular endothelial function in untreated hypertension remains insufficiently understood. This observational case-control study aims to compare circulating EEV concentrations between normotensive adults and adults with newly diagnosed, untreated primary hypertension. In addition, the study will investigate the associations between EEV levels, blood pressure, microvascular endothelial function assessed by laser Doppler flowmetry, and established circulating biomarkers of endothelial activation. The findings may improve understanding of the role of EEVs in early hypertension and support their potential use as non-invasive biomarkers of endothelial dysfunction and cardiovascular risk.Read full original descriptionShow less
Endothelial Extracellular Vesicles as Biomarkers of Blood Pressure-Induced Endothelial Activation in Adults With Newly Diagnosed Untreated Hypertension
Hypertension is associated with endothelial dysfunction, an early event in the development of cardiovascular disease. Endothelial extracellular vesicles (EEVs) have emerged as promising biomarkers of endothelial activation and vascular injury; however, their relationship with blood pressure and microvascular endothelial function in untreated hypertension remains insufficiently understood. This observational case-control study aims to compare circulating EEV concentrations between normotensive adults and adults with newly diagnosed, untreated primary hypertension. In addition, the study will investigate the associations between EEV levels, blood pressure, microvascular endothelial function assessed by laser Doppler flowmetry, and established circulating biomarkers of endothelial activation. The findings may improve understanding of the role of EEVs in early hypertension and support their potential use as non-invasive biomarkers of endothelial dysfunction and cardiovascular risk.
Inclusion: Adults aged 18 years or older; Ability and willingness to provide written informed consent; Normotensive individuals or individuals with newly diagnosed, previously untreated primary hypertension, classified according to the European Society of Hypertension (ESH) guidelines; Ability to comply with all study procedures.
Exclusion: Previous treatment with antihypertensive medication; Current use of oral contraceptives, hormone replacement therapy, or medications known to affect endothelial function; Secondary hypertension; History of cardiovascular disease (except newly diagnosed primary hypertension in the hypertensive group); Diabetes mellitus; Chronic kidney disease; Cerebrovascular disease; Peripheral arterial disease; Acute or chronic inflammatory or infectious disease; Active malignancy; Pregnancy or breastfeeding; Inability or unwillingness to provide informed consent.